Gregg Williams Purchases 1,737,765 Shares of Vivani Medical (NASDAQ:VANI) Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams acquired 1,737,765 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were bought at an average price of $1.14 per share, for a total transaction of $1,981,052.10. Following the purchase, the director directly owned 24,826,344 shares of the company’s stock, valued at approximately $28,302,032.16. This trade represents a 7.53% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Gregg Williams also recently made the following trade(s):

• On Saturday, November 15th, Gregg Williams bought 1,737,764 shares of Vivani Medical stock. The stock was purchased at an average price of $1.14 per share, with a total value of $1,981,050.96.
• On Monday, October 27th, Gregg Williams purchased 3,703,703 shares of Vivani Medical stock. The shares were purchased at an average cost of $1.62 per share, with a total value of $5,999,998.86.
• On Wednesday, October 15th, Gregg Williams purchased 1,737,764 shares of Vivani Medical stock. The shares were purchased at an average price of $1.14 per share, for a total transaction of $1,981,050.96.

Vivani Medical Stock Performance

VANI opened at $1.35 on Thursday. The company has a market capitalization of $98.48 million, a PE ratio of -3.00 and a beta of 3.24. The stock’s fifty day moving average is $1.47 and its 200-day moving average is $1.37. Vivani Medical, Inc. has a one year low of $0.91 and a one year high of $1.92.

Vivani Medical (NASDAQ:VANI) last released its earnings results on Thursday, November 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. On average, equities research analysts forecast that Vivani Medical, Inc. will post -0.41 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Wall Street Zen upgraded shares of Vivani Medical to a “sell” rating in a report on Saturday, November 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Vivani Medical in a report on Tuesday, September 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research report on Tuesday, October 14th. Finally, Zacks Research upgraded Vivani Medical from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 12th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Vivani Medical has a consensus rating of “Hold” and an average target price of $4.00.

Institutional Investors Weigh In On Vivani Medical

Hedge funds have recently made changes to their positions in the company. Connective Capital Management LLC boosted its position in shares of Vivani Medical by 796.2% in the first quarter. Connective Capital Management LLC now owns 162,098 shares of the company’s stock worth $170,000 after buying an additional 144,010 shares during the period. Panagora Asset Management Inc. purchased a new stake in Vivani Medical in the 2nd quarter worth about $25,000. Citadel Advisors LLC acquired a new stake in Vivani Medical during the 3rd quarter worth about $26,000. Finally, Susquehanna International Group LLP grew its stake in Vivani Medical by 100.5% during the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock valued at $46,000 after acquiring an additional 16,200 shares in the last quarter. Hedge funds and other institutional investors own 6.78% of the company’s stock.

Vivani Medical Company Profile

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.